Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs138213197
rs138213197
0.800 GeneticVariation BEFREE In conclusion, the G84E mutation of HOXB13, a relatively recent mutation that likely occurred in Northern Europe, significantly increases risk for PCa. 23393222

2013

dbSNP: rs138213197
rs138213197
0.800 GeneticVariation BEFREE This study confirms the overall importance of the HOXB13 G84E mutation in prostate cancer susceptibility. 23292082

2013

dbSNP: rs138213197
rs138213197
0.800 GeneticVariation BEFREE The G84E mutation predisposes to prostate cancer in Poland, but accounts for only a small proportion of cases. 23334858

2013

dbSNP: rs138213197
rs138213197
0.800 GeneticVariation BEFREE Our study has provided a population-based estimate of the average risk of prostate cancer for HOXB13 missense mutation G84E carriers that can be used to guide clinical practice and research. 23457453

2013

dbSNP: rs138213197
rs138213197
0.800 GeneticVariation BEFREE The G84E variant was detected in 4 patients (prevalence 0.42%, 95% CI 0.12-1.08), of whom 3 had prostate cancer on biopsy. 23036981

2013

dbSNP: rs138213197
rs138213197
0.800 GeneticVariation BEFREE These findings demonstrate that the HOXB13 G84E mutation is present in ~5 % of prostate cancer families, predominantly of European descent, and confirm its association with prostate cancer risk. 23064873

2013

dbSNP: rs138213197
rs138213197
0.800 GeneticVariation BEFREE The germline mutation G84E of HOXB13 is a rare but recurrent mutation associated with elevated risk of prostate cancer in men of European descent, with an effect size that is greater than observed for previously validated risk variants of genome wide association studies. 22714738

2012

dbSNP: rs138213197
rs138213197
0.800 GeneticVariation BEFREE The G84E mutation was more frequent among white case subjects than among white control subjects (10 of 1525 [0.7%] vs 2 of 1757 [0.1%], P = .01) and was associated with an increased risk of prostate cancer (unadjusted odds ratio = 5.8, 95% confidence interval = 1.3 to 26.5, P = .01). 22781434

2012